抗CD20单克隆抗体在儿童原发性难治性肾病综合征的应用新进展  

New progress of anti-CD20 monoclonal antibody therapy for children with idiopathic refractory nephrotic syndrome

作　　者：方香[1,2] 杨晓[1] 高春林[1] 夏正坤[1] 

机构地区：[1]南方医科大学金陵医院(南京军区南京总医院)儿科,南京210002 [2]安庆医药高等专科学校

出　　处：《医学研究生学报》2017年第3期315-318,共4页Journal of Medical Postgraduates

基　　金：国家自然科学基金(81270800)

摘　　要：原发性难治性肾病综合征(idiopathic refractory nephritic syndrome,IRNS)一直是临床治疗的棘手问题。抗CD20单克隆抗体是一种诱导B细胞溶解和凋亡的新型免疫抑制剂,其出现极大地改善了IRNS患者的预后。近年来,多数病例分析和临床试验对抗CD20单克隆抗体治疗儿童IRNS的有效性进行了报道。本文就抗CD20单克隆抗体的作用机制、在IRNS的临床应用、不良反应及研究中存在的问题进行综述。Idiopathic Refractory Nephrotic Syndrome （IRNS） has been an intractable problem in clinical treatment. Anti CD20 monoclonal antibody is a new type of immunosuppressive agent, which can induce the lysis and apoptosis of B cells. Significant-ly, it improves the prognosis of IRNS patients. In recent years, a number of case studies and clinical trials have been conducted on the effectiveness of anti CD20 monoclonal antibody in the treatment of children with IRNS. In this paper, the mechanism, clinical application, adverse effects and problems in the study of anti CD20 monoclonal antibody in IRNS will be reviewed.

关 键 词：肾病综合征 抗CD20单克隆抗体 利妥昔单抗 免疫抑制剂 儿童 

分 类 号：R692[医药卫生—泌尿科学]